A novel peroxisome proliferator-activated receptor α/γ agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells

Yu Hsun Kao, Hsing Pang Hsieh, Santhosh Kumar Chitlimalla, Wen Yu Pan, Ching Chuan Kuo, Yuan Chin Tsai, Wen Hsing Lin, Shuang En Chuang, Jang-Yang Chang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor (PPAR) γ agonists are used clinically for treating diabetes mellitus and cancer. 2-Methyl-2[(1-{3-phenyl- 7-propylbenzol[d]isoxazol-6-yl}oxy)propyl]-1H-4-indolyl) oxy]propanoic acid (BPR1H0101) is a novel synthetic indole-based compound, discovered through research to identify new PPARγ agonists, and it acts as a dual agonist for PPARγ and PPARα. Isobologram analysis demonstrated that BPR1H0101 is capable of antagonistic interaction with the topoisomerase (topo) II poison, VP16. A study of its mechanism showed that BPR1H0101 could inhibit the catalytic activity of topo II in vitro, but did not produce detectable topo II-mediated DNA strand breaks in human oral cancer KB cells. Furthermore, BPR1H0101 could inhibit VP16-induced topo II-mediated DNA cleavage and ataxia-telangiectasia- mutated phosphorylation in KB cells. The results suggest that BPR1H0101 can interfere with the topo II reaction by inhibiting catalytic activity before the formation of the intermediate cleavable complex; consequently, it can impede VP16-induced topo II-mediated DNA cleavage and cell death. This is the first identified PPARα/γ agonist that can serve as a topo II catalytic inhibitor, to interfere with VP16-induced cell death. The result might have relevance to the clinical use of the PPARα/γ agonist in combination chemotherapy.

Original languageEnglish
Pages (from-to)151-158
Number of pages8
JournalAnti-Cancer Drugs
Volume19
Issue number2
DOIs
Publication statusPublished - 2008 Feb 1

Fingerprint

Type II DNA Topoisomerase
Peroxisome Proliferator-Activated Receptors
Human Activities
KB Cells
Neoplasms
DNA Cleavage
Cell Death
Topoisomerase II Inhibitors
Ataxia Telangiectasia
DNA Breaks
Poisons
Mouth Neoplasms
Combination Drug Therapy
2-methyl-2-((1-(3-phenyl-7-propylbenzo(d)isoxazol-6-yl)oxy)propyl)-1H-4-indolyloxypropanoic acid
Diabetes Mellitus
Phosphorylation
Research

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Kao, Yu Hsun ; Hsieh, Hsing Pang ; Chitlimalla, Santhosh Kumar ; Pan, Wen Yu ; Kuo, Ching Chuan ; Tsai, Yuan Chin ; Lin, Wen Hsing ; Chuang, Shuang En ; Chang, Jang-Yang. / A novel peroxisome proliferator-activated receptor α/γ agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells. In: Anti-Cancer Drugs. 2008 ; Vol. 19, No. 2. pp. 151-158.
@article{780b615e29d34ebbaea23d2c98bf5309,
title = "A novel peroxisome proliferator-activated receptor α/γ agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells",
abstract = "Peroxisome proliferator-activated receptor (PPAR) γ agonists are used clinically for treating diabetes mellitus and cancer. 2-Methyl-2[(1-{3-phenyl- 7-propylbenzol[d]isoxazol-6-yl}oxy)propyl]-1H-4-indolyl) oxy]propanoic acid (BPR1H0101) is a novel synthetic indole-based compound, discovered through research to identify new PPARγ agonists, and it acts as a dual agonist for PPARγ and PPARα. Isobologram analysis demonstrated that BPR1H0101 is capable of antagonistic interaction with the topoisomerase (topo) II poison, VP16. A study of its mechanism showed that BPR1H0101 could inhibit the catalytic activity of topo II in vitro, but did not produce detectable topo II-mediated DNA strand breaks in human oral cancer KB cells. Furthermore, BPR1H0101 could inhibit VP16-induced topo II-mediated DNA cleavage and ataxia-telangiectasia- mutated phosphorylation in KB cells. The results suggest that BPR1H0101 can interfere with the topo II reaction by inhibiting catalytic activity before the formation of the intermediate cleavable complex; consequently, it can impede VP16-induced topo II-mediated DNA cleavage and cell death. This is the first identified PPARα/γ agonist that can serve as a topo II catalytic inhibitor, to interfere with VP16-induced cell death. The result might have relevance to the clinical use of the PPARα/γ agonist in combination chemotherapy.",
author = "Kao, {Yu Hsun} and Hsieh, {Hsing Pang} and Chitlimalla, {Santhosh Kumar} and Pan, {Wen Yu} and Kuo, {Ching Chuan} and Tsai, {Yuan Chin} and Lin, {Wen Hsing} and Chuang, {Shuang En} and Jang-Yang Chang",
year = "2008",
month = "2",
day = "1",
doi = "10.1097/CAD.0b013e3282f28fe",
language = "English",
volume = "19",
pages = "151--158",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

A novel peroxisome proliferator-activated receptor α/γ agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells. / Kao, Yu Hsun; Hsieh, Hsing Pang; Chitlimalla, Santhosh Kumar; Pan, Wen Yu; Kuo, Ching Chuan; Tsai, Yuan Chin; Lin, Wen Hsing; Chuang, Shuang En; Chang, Jang-Yang.

In: Anti-Cancer Drugs, Vol. 19, No. 2, 01.02.2008, p. 151-158.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel peroxisome proliferator-activated receptor α/γ agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells

AU - Kao, Yu Hsun

AU - Hsieh, Hsing Pang

AU - Chitlimalla, Santhosh Kumar

AU - Pan, Wen Yu

AU - Kuo, Ching Chuan

AU - Tsai, Yuan Chin

AU - Lin, Wen Hsing

AU - Chuang, Shuang En

AU - Chang, Jang-Yang

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Peroxisome proliferator-activated receptor (PPAR) γ agonists are used clinically for treating diabetes mellitus and cancer. 2-Methyl-2[(1-{3-phenyl- 7-propylbenzol[d]isoxazol-6-yl}oxy)propyl]-1H-4-indolyl) oxy]propanoic acid (BPR1H0101) is a novel synthetic indole-based compound, discovered through research to identify new PPARγ agonists, and it acts as a dual agonist for PPARγ and PPARα. Isobologram analysis demonstrated that BPR1H0101 is capable of antagonistic interaction with the topoisomerase (topo) II poison, VP16. A study of its mechanism showed that BPR1H0101 could inhibit the catalytic activity of topo II in vitro, but did not produce detectable topo II-mediated DNA strand breaks in human oral cancer KB cells. Furthermore, BPR1H0101 could inhibit VP16-induced topo II-mediated DNA cleavage and ataxia-telangiectasia- mutated phosphorylation in KB cells. The results suggest that BPR1H0101 can interfere with the topo II reaction by inhibiting catalytic activity before the formation of the intermediate cleavable complex; consequently, it can impede VP16-induced topo II-mediated DNA cleavage and cell death. This is the first identified PPARα/γ agonist that can serve as a topo II catalytic inhibitor, to interfere with VP16-induced cell death. The result might have relevance to the clinical use of the PPARα/γ agonist in combination chemotherapy.

AB - Peroxisome proliferator-activated receptor (PPAR) γ agonists are used clinically for treating diabetes mellitus and cancer. 2-Methyl-2[(1-{3-phenyl- 7-propylbenzol[d]isoxazol-6-yl}oxy)propyl]-1H-4-indolyl) oxy]propanoic acid (BPR1H0101) is a novel synthetic indole-based compound, discovered through research to identify new PPARγ agonists, and it acts as a dual agonist for PPARγ and PPARα. Isobologram analysis demonstrated that BPR1H0101 is capable of antagonistic interaction with the topoisomerase (topo) II poison, VP16. A study of its mechanism showed that BPR1H0101 could inhibit the catalytic activity of topo II in vitro, but did not produce detectable topo II-mediated DNA strand breaks in human oral cancer KB cells. Furthermore, BPR1H0101 could inhibit VP16-induced topo II-mediated DNA cleavage and ataxia-telangiectasia- mutated phosphorylation in KB cells. The results suggest that BPR1H0101 can interfere with the topo II reaction by inhibiting catalytic activity before the formation of the intermediate cleavable complex; consequently, it can impede VP16-induced topo II-mediated DNA cleavage and cell death. This is the first identified PPARα/γ agonist that can serve as a topo II catalytic inhibitor, to interfere with VP16-induced cell death. The result might have relevance to the clinical use of the PPARα/γ agonist in combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=37849010055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849010055&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3282f28fe

DO - 10.1097/CAD.0b013e3282f28fe

M3 - Article

VL - 19

SP - 151

EP - 158

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -